Derma Sciences Inc. (NASDAQ:DSCI)’s share price rose 6.2% on Wednesday . The stock traded as high as $4.48 and last traded at $4.31, with a volume of 170,911 shares traded. The stock had previously closed at $4.06.

Separately, Zacks Investment Research downgraded shares of Derma Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $7.45.

The company’s 50-day moving average price is $4.04 and its 200-day moving average price is $3.60. The stock’s market capitalization is $111.57 million.

Derma Sciences (NASDAQ:DSCI) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.06. The firm earned $20.20 million during the quarter, compared to the consensus estimate of $20.60 million. Equities research analysts predict that Derma Sciences Inc. will post ($0.20) EPS for the current fiscal year.

A hedge fund recently raised its stake in Derma Sciences stock. Royce & Associates LLC boosted its position in Derma Sciences Inc. (NASDAQ:DSCI) by 7.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 237,507 shares of the company’s stock after buying an additional 16,000 shares during the period. Royce & Associates LLC owned about 0.92% of Derma Sciences worth $1,085,000 at the end of the most recent quarter.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.